Fundamental Analysis of Edwards Lifesciences Corp - Growth / Value Index
EW - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.069
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 18.75
Price to Book Ratio of 7.93 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 38.36 | 37.96 | 3.84 % | |
| Price to Book | 8.17 | 8.08 | -15.63 % | 7.49 |
| Price to Sales | 8.82 | 9.34 | -9.70 % | |
| Enterprise Value to EBITDA Multiple | 34.69 | 34.17 | 18.42 % |
EW - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Excellent Net Margin for last 3 years
Over the last 3 years, the company has achieved Incredible Return on Equity
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 21.54%
All key Trailing Twelve Months Margin growing by 15 %
Good Return On Capital Employed of 19.71
Good Net Margin of 22.99% is achieved by the company
Low Earning Yield of 2.69 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 21.54 | 21.52 | -17.90 % | 4.94 |
| Return On Asset | 15.31 | 15.28 | -16.73 % | 3.61 |
| Net Profit Margin | 22.99 | 24.59 | -13.03 % | 22.02 |
| Operating Profit Margin | 24.98 | 30.05 | -7.50 % | 24.25 |
| EBITDA Margin | 24.96 | 27.06 | -24.28 % | 24.25 |
Highlights
| Market Cap | 53715.76 M |
| Enterprise Value | 53193.66 M |
| Price/Book TTM | 8.17 |
| Outstanding Share | 602600 K |
| Float/ Outstanding Share | 98.99% |
| Dividend Yield | 2.23 % |
Share Holding
Guru Numbers
| Price/Graham No | 3.71 |
| Peter Lynch Ratio | -0.096 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 15.02 |
| Sloan Ratio | 0.0415 |
| Peter Lynch Fair Value | 29.35 |
EW - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 6143.40 M | 8.11 % | 4.18 % |
| Gross Profit | 4707.50 M | 5.49 % | 3.01 % |
| EBITDA | 1533.20 M | 18.14 % | 3.15 % |
| Net Profit | 1412.20 M | 5.98 % | 4.87 % |
| EPS | 2.32 | 3.70 % | NA |
EW - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 87.50
Altman Z Score of 14.66 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.094 | -12.67 % | 0.087 |
| Cash Ratio | 1.38 | 15.73 % | |
| Quick Ratio | 2.40 | 10.46 % | 2.67 |
| Shareholders Equity | 71.02 | 1.43 % | |
| Debt to EBITDA | 0.395 | 22.17 % |
Historical Valuation Ratios of Edwards Lifesciences Corp
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Edwards Lifesciences Corp
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Edwards Lifesciences Corp
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Edwards Lifesciences Corp
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)